Physician profile
Forrest Patrick Murphy
NPI 1265444541
$5,782.54
in general payments reported to CMS, 2019-2025
19 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $293 · 2021: $480 · 2022: $978 · 2023: $225 · 2024: $2,233 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,749 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,748.91 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $2,218.21 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $1,005.84 | 2024-2025 | Purified Cortrophin Gel |
| Alcon Vision LLC | $724.75 | 2019-2025 | Clareon, Tryptyr, Hydrus Microstent |
| New World Medical,INC. | $698.27 | 2022 | |
| Horizon Therapeutics Plc | $168.03 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $150.93 | 2019-2024 | Tecnis Simplicity |
| Alimera Sciences, INC. | $135.51 | 2019-2020 | |
| Glaukos Corporation | $115.46 | 2019 | |
| Ocular Therapeutix, INC. | $106.52 | 2023 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $101.55 | 2024-2025 | Xdemvy |
| Amgen INC. | $84.38 | 2024-2025 | Tepezza |
| Dompe US, INC. | $79.28 | 2024-2025 | Oxervate |
| Rxsight INC | $54.04 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $42.04 | 2023 | |
| Bausch & Lomb Americas INC. | $24.97 | 2024 | Xiidra, Miebo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.92 | 2021 | |
| Harrow Eye, LLC | $24.33 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.68 | 2020 | |
| Travere Therapeutics, INC. | $0.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Forrest Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.